Evidence map›Paper›PMID 41635308›Full record

ReviewBiosafety and health2025

Advances in the development of infectious clones of human coronaviruses and related applications.

Guanya Liu, Ruixiao Tan, Yiyi Wu, Mengwei Wang, Baoying Huang, Wenjie Tan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biosafety and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guanya LiuSchool of Public Health, Baotou Medical College, Baotou 011400, China.
Ruixiao TanCollege of Life Sciences, Beijing Normal University, Beijing 100875, China.
Yiyi WuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Health Commissions Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Mengwei WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Health Commissions Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Baoying HuangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Health Commissions Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Wenjie TanSchool of Public Health, Baotou Medical College, Baotou 011400, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronaviruses can infect humans, mammals, and birds, leading to respiratory, gastrointestinal, and neurological diseases. These viruses are significant zoonotic pathogens with nine known types capable of infecting humans. The coronavirus genome, approximately 30 kb in size, is the largest known ribonucleic acid (RNA) virus genome, and its complexity makes assembly and manipulation time-consuming and labor-intensive. Reverse genetic systems are widely used to engineer recombinant viruses that can be adapted at Biosafety Level 2 (BSL-2) for studying viral gene function, replication, pathogenesis, vaccines, and therapeutics. The infectious clones, which enabled the recovery of various viruses after DNA recombinant technology, were indispensable tools for the reverse genetics of viruses. Various techniques for constructing infectious clones of human coronaviruses (HCoV) have been developed, encompassing methods such as vaccinia virus vectors method,

Indexed as

ApplicationHuman coronavirusesInfectious clonesReverse genetics

Identifiers

PMID41635308
PMCPMC12861752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.